GlassScriptPhysician profile
Sasha Hamdani
NPI 1063772754
$103,907.42
in general payments reported to CMS, 2019-2025
31 companies · $60K in 2025
The $60K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,193 · 2020: $376 · 2021: $119 · 2022: $415 · 2023: $1,025 · 2024: $39K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Honoraria: $38K · Food and Beverage: $2,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,000.00 |
| Honoraria | $38,200.00 |
| Food and Beverage | $2,603.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $78,396.94 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $20,449.92 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $928.03 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $707.57 | 2021-2025 | |
| Lundbeck LLC | $562.32 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $369.78 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $331.88 | 2019-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $208.79 | 2019-2020 | |
| Allergan, INC. | $206.44 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $196.02 | 2019-2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $185.22 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $169.83 | 2019-2022 | |
| Neos Therapeutics, LP | $169.80 | 2019-2023 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.50 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $125.18 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $111.42 | 2019 | |
| Axsome Therapeutics, INC. | $107.57 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $96.12 | 2019-2025 | Aplenzin |
| Alkermes, INC. | $81.08 | 2022-2024 | Aristada, Lybalvi |
| Tris Pharma INC | $57.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $47.79 | 2019-2020 | |
| Corium, LLC | $41.18 | 2022-2023 | Azstarys |
| Eisai INC. | $33.07 | 2020 | |
| Jazz Pharmaceuticals INC. | $32.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.81 | 2024 | Cobenfy |
| Biogen, INC. | $20.66 | 2024 | |
| Alfasigma USA, INC. | $20.49 | 2020 | |
| Merck Sharp & Dohme LLC | $17.74 | 2023 | Belsomra |
| Acadia Pharmaceuticals INC | $17.04 | 2024 | Nuplazid |
| Almatica Pharma LLC | $16.09 | 2024 | Loreev Xr |
| Amgen INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Hamdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.